NEPSEtrading

Live NEPSE data, charts, broker analysis and portfolio tools for investors in Nepal.

Subscribe to our newsletter

Weekly insights from the NEPSE market in your inbox.

Marketminds Investment Group Private Limited

Registration
DOIB certificate no. 4680-2081/2082
Editor-in-chief
Dipesh Ghimire, Director
9802363868, 9851119988
Office
Koteshwor 32, Kathmandu
Phone
01-5253221, +977 9709066745
Email

Contact support

Market

  • Stocks
  • Sectors

Company

  • About Us
  • Our Team
  • Terms of Use
  • Our Policy
  • Training
  • Contact Us

Help

  • Support
  • Report
  • FAQ

Get the app

Markets, signals and alerts on your phone.

Get it onGoogle Play

More from NEPSE Trading

  • Stock EducationFree share market courses
  • EconomyNepal and world economic data
  • BFIS CompareBank rates, loans and insurance
  • Nepal's CapitalsMutual fund NAV and dividends
  • JobsNepalJobs in Nepal

nepsetrading.com is an online news portal that provides insights into trading and investment by analyzing the stock market and the global economy. We create charts based on the analysis of various indicators. Please do not rely solely on this information for investment decisions. Self-study is crucial. Use this information only as an educational and informational resource.

© 2026 nepsetrading.com. All rights reserved. Owned and operated by Marketminds Investment Group Private Limited.·Charts powered by TradingView

  • Portfolio
  • Explore
  • Calendar
  • Chart
  • Social
  • News
  • Account
  1. News
  2. Stock
  3. Om Megashree Pharmaceuticals Posts Stable Growth in Q4, Profit Margins Decline Slightly

ओम मेगाश्री फार्मास्युटिकल्सको चौथो त्रैमासिक नतिजा : आम्दानीमा वृद्धि, नाफा मार्जिनमा केही गिरावटOm Megashree Pharmaceuticals Posts Stable Growth in Q4, Profit Margins Decline Slightly

NEPSE TRADINGPublished on August 18, 20251 min read
ओम मेगाश्री फार्मास्युटिकल्सको चौथो त्रैमासिक नतिजा : आम्दानीमा वृद्धि, नाफा मार्जिनमा केही गिरावट

ओम मेगाश्री फर्मास्युटिकल्स लिमिटेड (OMPL) ले आ.व. २०८१/८२ को चौथो त्रैमासको लेखापरीक्षित नतिजा प्रकाशित गरेको छ। नतिजा अनुसार कम्पनीले आम्दानीमा निरन्तर वृद्धि देखाए पनि नाफा र बजार मूल्यबीच ठूलो अन्तर देखिएको छ।

चौथो त्रैमासमा कम्पनीको कुल आम्दानी २७ करोड ७७ लाख ९६ हजार रुपैयाँ पुगेको छ, जुन तेस्रो त्रैमासको २१ करोड ५१ लाख रुपैयाँ र दोस्रो त्रैमासको १३ करोड ६१ लाख रुपैयाँभन्दा उच्च हो। यस अवधिमा कम्पनीले १७ करोड ९८ लाख रुपैयाँ सकल नाफा आर्जन गरेको छ। तर नाफा मार्जिन घट्दै गएको छ—दोस्रो त्रैमासमा ८७.०९% रहेको सकल नाफा मार्जिन चौथो त्रैमासमा ६४.६९% मा झरेको छ।

शुद्ध नाफा चौथो त्रैमासमा ८९ लाख २८ हजार रुपैयाँ पुगेको छ, जुन तेस्रो त्रैमासको ७५ लाख ६० हजार रुपैयाँभन्दा थोरै वृद्धि हो। तर शुद्ध नाफा मार्जिन करिब ३–३.५% वरिपरि मात्र देखिएको छ। कम्पनीको प्रतिशेयर आम्दानी (EPS) वार्षिकीकृत आधारमा १.४९ रुपैयाँमा घटेको छ, जुन दोस्रो त्रैमासमा १.९७ रुपैयाँ थियो।

यद्यपि नाफा सानो देखिए पनि, कम्पनीको सेयर बजार मूल्य प्रति सेयर १,५१७.७६ रुपैयाँमा कारोबार भइरहेको छ। यसको रिपोर्टेड पीई अनुपात १,०१९.९६ पुगेको छ, जुन अत्यन्तै उच्च हो। पुस्तक मूल्य (Book Value) भने मात्र १०३.९४ रुपैयाँ रहेको छ। यस त्रैमासमा कम्पनीले लाभांश घोषणा गरेको छैन।

Om Megashree Pharmaceuticals Limited (OMPL) has released its audited financial results for the fourth quarter of FY 2024/25, showing steady growth in revenue but relatively modest profitability compared to its market valuation.

The company reported a total revenue of Rs. 277.96 million in Q4, up from Rs. 215.11 million in Q3 and Rs. 136.15 million in Q2, reflecting a continuous improvement in sales performance throughout the year. Gross profit for the quarter stood at Rs. 179.81 million, maintaining strong efficiency despite a decline in margin from 87.09% in Q2 to 64.69% in Q4.

Net income in Q4 was recorded at Rs. 8.92 million, slightly higher than Rs. 7.56 million in Q3, but with net profit margins hovering around a low 3–3.5% range. The company’s annualized earnings per share (EPS) stood at Rs. 1.49 in Q4, declining from Rs. 1.97 in Q2, reflecting weaker profitability growth relative to revenue expansion.

Despite its modest earnings, OMPL’s shares are trading at a steep price of Rs. 1,517.76 per share in the secondary market, giving it an extremely high reported price-to-earnings (PE) ratio of 1,019.96. The book value per share, in contrast, is only Rs. 103.94, highlighting a large premium investors are paying for the stock. The company has not announced any dividend distribution so far.

Trending News

  • देशभरको मौसम मुख्यतया सफा, कोशीको तराईमा हल्का वर्षाको सम्भावनाWeather Mainly Fair Across Nepal, Light Rain Likely in Koshi Terai

    NEPSE TRADING21 Nov, 2026

  • राष्ट्र बैंकद्वारा विदेशी मुद्राको विनिमयदर सार्वजनिक : अमेरिकी डलरको बिक्रीदर १४८ रुपैयाँ ५८ पैसाNRB Sets Foreign Exchange Rates: US Dollar Selling Rate at Rs 148.58

    NEPSE TRADING21 Nov, 2026

  • परिसूचक ओरालो लाग्दा पनि बढ्यो कारोबार, प्राविधिक विन्दु र सस्ता सेयरमा लगानीकर्ताको नजरTurnover Rises Despite Index Decline as Investors Eye Technical Levels and Bargain Stocks

    NEPSE TRADING20 Nov, 2026

Related News

  • देशभरको मौसम मुख्यतया सफा, कोशीको तराईमा हल्का वर्षाको सम्भावनाWeather Mainly Fair Across Nepal, Light Rain Likely in Koshi Terai
  • राष्ट्र बैंकद्वारा विदेशी मुद्राको विनिमयदर सार्वजनिक : अमेरिकी डलरको बिक्रीदर १४८ रुपैयाँ ५८ पैसाNRB Sets Foreign Exchange Rates: US Dollar Selling Rate at Rs 148.58
  • परिसूचक ओरालो लाग्दा पनि बढ्यो कारोबार, प्राविधिक विन्दु र सस्ता सेयरमा लगानीकर्ताको नजरTurnover Rises Despite Index Decline as Investors Eye Technical Levels and Bargain Stocks
  • प्रधानमन्त्री शाहको दिल्ली यात्रा ‘छोटो र कार्यमूलक’, हवाईमार्ग र मल कारखाना मुख्य एजेण्डाPM Shah’s Delhi Trip ‘Short and Functional,’ Air Routes and Fertilizer Plant Top Agenda
  • संसद्‌मा बहस र समितिका बैठक सुस्त, माननीयहरू भने ‘विदेश मोह’ मा मस्त : सात महिनामा ४९ को औपचारिक उडान, अनौपचारिकको हिसाबै छैनParliamentary Debates and Committee Meetings Stall as Lawmakers Embark on Foreign Junkets: 49 on Official Record in Seven Months, Unrecorded Trips Countless